159 related articles for article (PubMed ID: 35752711)
21. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
[TBL] [Abstract][Full Text] [Related]
22. Expression Levels of IL-17A, IL-17F, IL-17RA, and IL-17RC in Prostate Cancer with Taking into Account the Histological Grade according to Gleason Scale in Comparison to Benign Prostatic Hyperplasia: In Search of New Therapeutic Options.
Janiczek M; Szylberg Ł; Antosik P; Kasperska A; Marszałek A
J Immunol Res; 2020; 2020():4910595. PubMed ID: 32537467
[TBL] [Abstract][Full Text] [Related]
23. Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Sloane BF; Gleason DF
Prostate; 2001 Sep; 48(4):274-84. PubMed ID: 11536307
[TBL] [Abstract][Full Text] [Related]
24. NMR spectroscopy of filtered serum of prostate cancer: A new frontier in metabolomics.
Kumar D; Gupta A; Mandhani A; Sankhwar SN
Prostate; 2016 Sep; 76(12):1106-19. PubMed ID: 27197810
[TBL] [Abstract][Full Text] [Related]
25. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
26. Ribonuclease 4 protects neuron degeneration by promoting angiogenesis, neurogenesis, and neuronal survival under stress.
Li S; Sheng J; Hu JK; Yu W; Kishikawa H; Hu MG; Shima K; Wu D; Xu Z; Xin W; Sims KB; Landers JE; Brown RH; Hu GF
Angiogenesis; 2013 Apr; 16(2):387-404. PubMed ID: 23143660
[TBL] [Abstract][Full Text] [Related]
27. TAZ is overexpressed in prostate cancers and regulates the proliferation, migration and apoptosis of prostate cancer PC3 cells.
Lin M; Bu C; He Q; Gu J; Wang H; Feng N; Jiang SW
Oncol Rep; 2020 Aug; 44(2):747-756. PubMed ID: 32468018
[TBL] [Abstract][Full Text] [Related]
28. Serum levels of secreted group IIA phospholipase A(2) in benign prostatic hyperplasia and prostate cancer: a biomarker for inflammation or neoplasia?
Menschikowski M; Hagelgans A; Fuessel S; Mareninova OA; Neumeister V; Wirth MP; Siegert G
Inflammation; 2012 Jun; 35(3):1113-8. PubMed ID: 22189868
[TBL] [Abstract][Full Text] [Related]
29. Metabolomic Prediction of Human Prostate Cancer Aggressiveness: Magnetic Resonance Spectroscopy of Histologically Benign Tissue.
Vandergrift LA; Decelle EA; Kurth J; Wu S; Fuss TL; DeFeo EM; Halpern EF; Taupitz M; McDougal WS; Olumi AF; Wu CL; Cheng LL
Sci Rep; 2018 Mar; 8(1):4997. PubMed ID: 29581441
[TBL] [Abstract][Full Text] [Related]
30. Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate-specific antigen.
Feng J; Gang F; Li X; Jin T; Houbao H; Yu C; Guorong L
Int Urol Nephrol; 2013 Aug; 45(4):1023-8. PubMed ID: 23779229
[TBL] [Abstract][Full Text] [Related]
31. POLYAMINES AS NEW POTENTIAL BIOMARKERS FOR DIFFERENTIAL DIAGNOSIS OF PROSTATE CANCER AND ESTIMATION OF ITS AGGRESSIVENESS.
Zaletok SP; Klenov OO; Bentrad VV; Prylutskyi MP; Vitruk YV; Stakhovsky EO; Timoshenko AV
Exp Oncol; 2022 Aug; 44(2):148-154. PubMed ID: 35964654
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
33. The expression and localization of estrogen receptor beta in hyperplastic and neoplastic prostate lesions.
Levakov AF; Kaćanski MM; Vucković N; Zivojinov M; Amidzić J; Sabo JI
Vojnosanit Pregl; 2015 Oct; 72(10):906-13. PubMed ID: 26665557
[TBL] [Abstract][Full Text] [Related]
34. The relation of beclin 1 and bcl-2 expressions in high grade prostatic intraepithelial neoplasia and prostate adenocarcinoma: a tissue microarray study.
Baspinar S; Bircan S; Orhan H; Kapucuoglu N; Bozkurt KK
Pathol Res Pract; 2014 Jul; 210(7):412-8. PubMed ID: 24690321
[TBL] [Abstract][Full Text] [Related]
35. Comparative analysis of biological profiles of benign prostate hyperplasia and prostate cancer as potential diagnostic, prognostic and predictive indicators.
Makarewicz R; Zyromska A; Andrusewicz H
Folia Histochem Cytobiol; 2011; 49(3):452-7. PubMed ID: 22038225
[TBL] [Abstract][Full Text] [Related]
36. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
37. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
38. Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis.
Sinha AA; Gleason DF; Staley NA; Wilson MJ; Sameni M; Sloane BF
Anat Rec; 1995 Mar; 241(3):353-62. PubMed ID: 7538734
[TBL] [Abstract][Full Text] [Related]
39. Temporal Trend in Incidental Prostate Cancer Detection at Surgery for Benign Prostatic Hyperplasia.
Capogrosso P; Capitanio U; Vertosick EA; Ventimiglia E; Chierigo F; Oreggia D; Moretti D; Briganti A; Vickers AJ; Montorsi F; Salonia A
Urology; 2018 Dec; 122():152-157. PubMed ID: 30138683
[TBL] [Abstract][Full Text] [Related]
40. SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.
Bauman TM; Becka AJ; Sehgal PD; Huang W; Ricke WA
Hum Pathol; 2015 Nov; 46(11):1744-51. PubMed ID: 26344417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
